Harvard Bioscience, Inc.
HBIO
$5.37
-$0.18-3.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 86.55M | 87.37M | 88.75M | 91.40M | 94.14M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 86.55M | 87.37M | 88.75M | 91.40M | 94.14M |
| Cost of Revenue | 36.64M | 37.58M | 38.21M | 39.18M | 39.33M |
| Gross Profit | 49.91M | 49.79M | 50.54M | 52.22M | 54.81M |
| SG&A Expenses | 35.56M | 37.76M | 39.53M | 41.81M | 43.52M |
| Depreciation & Amortization | 4.03M | 4.43M | 4.91M | 5.08M | 5.26M |
| Other Operating Expenses | 171.00K | 171.00K | 171.00K | 24.00K | 819.00K |
| Total Operating Expenses | 85.22M | 88.91M | 92.23M | 95.93M | 99.32M |
| Operating Income | 1.33M | -1.54M | -3.48M | -4.53M | -5.19M |
| Income Before Tax | -57.39M | -53.59M | -56.95M | -57.98M | -11.67M |
| Income Tax Expenses | -686.00K | 243.00K | 457.00K | 76.00K | 740.00K |
| Earnings from Continuing Operations | -56.70 | -53.84 | -57.41 | -58.05 | -12.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.70M | -53.84M | -57.41M | -58.05M | -12.41M |
| EBIT | 1.33M | -1.54M | -3.48M | -4.53M | -5.19M |
| EBITDA | 7.27M | 4.82M | 3.37M | 2.50M | 1.97M |
| EPS Basic | -12.85 | -12.20 | -13.03 | -13.19 | -2.85 |
| Normalized Basic EPS | -1.25 | -0.71 | -1.18 | -1.26 | -1.33 |
| EPS Diluted | -12.87 | -12.23 | -13.03 | -13.19 | -2.87 |
| Normalized Diluted EPS | -1.25 | -0.71 | -1.18 | -1.26 | -1.33 |
| Average Basic Shares Outstanding | 17.76M | 17.66M | 17.57M | 17.49M | 17.42M |
| Average Diluted Shares Outstanding | 17.76M | 17.74M | 17.65M | 17.57M | 17.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |